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Summary PurposeWe aimed to investigate the recommend-
ed dose for the combination of TSU-68, a multiple-receptor
tyrosine kinase inhibitor targeting vascular endothelial growth
factor receptor-2 and platelet-derived growth factor
receptor-β, and S-1, an oral fluoropyrimidine, in patients with
advanced hepatocellular carcinoma (HCC) based on its asso-
ciated dose-limiting toxicity (DLT) frequency. We also deter-
mined the safety, tolerability, pharmacokinetics (PK), and
efficacy of the combination treatment. Patients and methods
Patients without any prior systemic therapy received 400 mg/
day TSU-68 orally and 80 mg/day (level 1) or 100 mg/day
(level 2) S-1 for 4 or 2 weeks followed by a 2- or 1-week rest
period (groups A and B, respectively). According to the
treatment, patients progressed from level 1B to level 2A, then
level 2B. Safety and response rates were assessed. Results
Eighteen patients were enrolled. Two patients at levels 1B and
2A but none at level 2B showed DLTs. The common adverse
drug reactions were a decrease in hemoglobin levels, hypoal-
buminemia, and anorexia, which were mild in severity (grades
1–2). PK data from levels 1B and 2A indicated that the area
under the curve for TSU-68 and 5-fluorouracil was unlikely to
be affected by the combination treatment. Response rate,
disease control rate, median time to progression, and median
overall survival were 27.8 %, 61.1 %, 5.3 months, and
12.8 months, respectively. Conclusion The recommended
dose for advanced HCC should be 400 mg/day TSU-68 and
100 mg/day S-1 for 4 weeks followed by 2-week rest.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide [1]. Surgical resection, percutaneous etha-
nol injection (PEI), or radiofrequency ablation (RFA) is often
performed in patients with curable HCC, whereas transcathe-
ter arterial chemoembolization (TACE) is the treatment of
choice for patients with incurable HCC. Sorafenib is the
standard chemotherapy for HCC [2, 3], but its efficacy is
limited. Therefore, the search for novel medical therapies is
essential for HCC management.
As HCC is a highly vascular tumor, a number of anti-
angiogenic agents have been tested for its treatment. TSU-68
M. Ikeda (*) :K. Nakachi : S. Mitsunaga : S. Shimizu :Y. Kojima
Department of Hepatobiliary and Pancreatic Oncology,




Department of Gastroenterology, Graduate School of Medicine,
Juntendo University, Tokyo, Japan
Y. Kojima
Department of Gastroenterology, National Center for Global Health
and Medicine, Tokyo, Japan
H. Ueno :C. Morizane : S. Kondo :Y. Sakamoto : T. Okusaka
Department of Hepatobiliary and Pancreatic Oncology,
National Cancer Center Hospital, Tokyo, Japan
S. Shiina :Y. Asaoka : R. Tateishi :K. Koike
Department of Gastroenterology, Graduate School of Medicine,
The University of Tokyo, Tokyo, Japan
H. Arioka
Department of Medical Oncology, Yokohama Rosai Hospital,
Yokohama, Japan
Invest New Drugs (2014) 32:928–936
DOI 10.1007/s10637-014-0109-2
is a small-molecule, orally administered, multiple-receptor
tyrosine kinase inhibitor of the vascular endothelial growth
factor receptor-2 (VEGFR-2) and platelet-derived growth fac-
tor receptor-β (PDGFR-β) [4–8]. TSU-68 demonstrated fa-
vorable efficacy and a good safety profile for HCC [9, 10]. A
phase I I I c l in ica l t r i a l o f TSU-68 wi th TACE
(ClinicalTrials.gov identifier NCT01465464 ORIENTAL
study) is currently underway.
S-1 is an orally administered fluoropyrimidine anticancer
drug that combines tegafur (FT) , 5-chloro-2 ,4-
dihydroxypyridine (CDHP), and oteracil potassium (Oxo) in
a molar concentration ratio of 1:0.4:1 [11]. CDHP is a com-
petitive inhibitor of dihydropyrimidine dehydrogenase
(DPD), a 5-fluorouracil (5-FU)-metabolizing enzyme
expressed in the liver. Therefore, prolonged effective concen-
trations of 5-FU in the plasma and tumor tissue can be
achieved via successful inhibition of DPD by CDHP. Oxo, a
competitive inhibitor of orotate phosphoribosyltransferase,
inhibits the phosphorylation of 5-FU in the gastrointestinal
tract, thereby reducing serious 5-FU-related gastrointestinal
toxicity. Clinically, S-1 has been shown to be effective against
various solid tumors. In Japan, the clinical development of
chemotherapies for unresectable, advanced, or recurrent gas-
tric cancers has progressed for many years, and many clinical
studies have been conducted. S-1 has showed favorable effi-
cacy and a good safety profile for HCC in a phase I/II study
[12]. A phase III clinical trial of S-1 for HCC (Japicdoc
identifier JapicCTI-090920 S-CUBE trial) is underway.
Many molecular targeted drugs and anticancer agents have
been administered as combination therapies to improve effi-
cacy in various types of cancer. In HCC, combination thera-
pies of molecular targeted agents [13], a molecular-targeted
agent and cytotoxic chemotherapy [14–18], and a molecular
targeted agent and TACE have been developed [19, 20].
However, no combination therapy has been proven to improve
survival [21]. TSU-68 and S-1 have been shown to be effec-
tive against HCC in a phase I/II study as single agents.
Therefore, we investigated the TSU-68 plus S-1 combination.
This study investigated the recommended dose of TSU-68
plus S-1 in HCC based on the frequency of associated dose-
limiting toxicity (DLT). We determined safety, tolerability,
pharmacokinetics (PK), and efficacy of the TSU-68 plus S-1
combination in patients with advanced HCC. We also evalu-
ated the expression of endothelial cell markers in patients
receiving TSU-68 plus S-1 combination therapy.
Methods
Eligibility criteria
The following patients were eligible: (1) patients with con-
firmed HCC according to histological studies or diagnostic
imaging; (2) patients classified as having advanced disease if
they were not eligible for or showed disease progression after
surgery, PEI, RFA, or TACE; (3) patients with a minimum age
of 20 years; (4) patients with an Eastern Cooperative
Oncology Group performance status scale score of 0 or 1;
(5) patients with measurable disease based on the Response
Evaluation Criteria in Solid Tumors (RECIST) v1.0; and (6)
patients with a white blood cell count of ≥3,000 cells/mm3 or
neutrophil count of ≥1,500 cells/mm3, hemoglobin level of
≥9.0 g/dL, platelet count of ≥7.5×104 cells/mm3, total biliru-
bin level of 2.0 mg/dL, aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) levels≤upper limit of nor-
mal×5, albumin level of ≥3.0 mg/dL, prothrombin time-
international normalized ratio of ≤2.0, and creatinine level≤
upper limit of normal.
Patients were not eligible if they had received surgery, PEI,
RFA, TACE, chemotherapy, or radiotherapy within 30 days
before the start of this study. Patients were excluded if there
was clinical evidence of central nervous system metastasis,
severe cardiovascular disorder, hepatic encephalopathy, un-
controllable pleural effusion or ascites, or a serious infection.
Patients requiring prophylactic variceal ligation or sclerother-
apy were also excluded.
All patients provided written informed consent. The study
was approved by the institutional review board of each of the
3 participating hospitals and was performed in accordance
with the principles of the Declaration of Helsinki and Good
Clinical Practice Guidelines.
DLTs
The following were considered as DLTs: (1) a hematological
adverse drug reaction of grade 4 (grade 3 febrile neutropenia),
(2) a non-hematological adverse drug reaction of grade 3
(excluding AST, ALT, alkaline phosphatase, gamma-
glutamyl transpeptidase, Na, and K levels), (3) AST and
ALT levels of 10 times higher than the upper limit of normal
values, (4) an adverse drug reaction requiring discontinuation
of TSU-68 treatment for 15 consecutive days during a cycle,
(5) an adverse drug reaction requiring discontinuation of S-1
treatment for 8 consecutive days during a cycle, and (6) an
adverse drug reaction requiring discontinuation of TSU-68
plus S-1 treatment.
Study design and treatment
The present study was designed as an open-label phase I
study. The patients received 400 mg/day TSU-68 orally and
one of the following doses of S-1: 50 mg/day (level 0), 80 mg/
day (level 1), or 100 mg/day (level 2). TSU-68 and S-1 were
administered orally twice daily (after breakfast and supper).
For S-1, dose levels were administered according to the fol-
lowing administration and resting schedules: for levels 0B,
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1B, and 2B, S-1 was administered continuously for 28 days
followed by a 14-day rest period, which completed a
treatment cycle, and for levels 0A, 1A, and 2A, a cycle
of S-1 was defined as continuous administration of the
drug for 14 days followed by a 7-day rest period. Drug
administration was continued by repeating the cycle, un-
less one of the following occurred: progressive disease,
unacceptable toxicity, withdrawal of patient consent, or
termination of treatment at the attending physician’s dis-
cretion. Treatment dose and duration started at level 1B,
followed by progression to 2A–2B or 1A–0A in the event
of DLTs (Fig. 1). The recommended dose was determined
based on the treatment dose, duration, DLTs, toxicity, and
efficacy.
Assessment of efficacy and toxicity
DLTs were recorded for each treatment level, and the rate of
DLT development was determined. During each course of
treatment, the tumor response was assessed according to
RECIST v1.0 by using computed tomography or magnetic
resonance imaging, with a maximum slice thickness of 5 mm
[22]. Efficacy was evaluated in terms of the response rate
(RR), disease control rate (DCR), median time to progression
(TTP), and median overall survival (OS) time. TTP was
defined as the time from the date of registration to the date
when progressive disease was confirmed based on RECIST.
OS was defined as the time from the date of registration to the
date of death. Physical examination findings and results of
serum and urine chemistry analyses were obtained at 1-week
intervals for the first cycle and at 2-week intervals during the
remaining cycles. Vital signs were assessed as necessary. The
severity of all adverse events was evaluated according to the
Common Terminology Criteria for Adverse Events, version
3.0.
PK
We evaluated the PK of co-administered TSU-68 and S-1 on
the basis of their plasma concentrations and PK parameters
obtained in 12 patients at levels 1B and 2A. Blood samples
were collected before dosing and at 1, 2, 3, 4, 6, 9, and 12 h on
days 1 and 8 after dosing. TSU-68 plasma concentration was
determined using a validated ultraviolet high-performance
liquid chromatography method. Plasma concentrations of
FT, 5-FU, CDHP, and Oxo were determined using a validated
liquid chromatography-tandem mass spectrometry method.
PK parameters, including maximum plasma concentration
(Cmax), time to reach the maximum plasma concentration,
area under curve (AUC), and plasma half-life, were calculated
with the non-compartmental method using the PK analysis
program WinNonlin Professional (Pharsight Corporation, St.
Louis, MO).
Endothelial cell markers
Blood samples were collected from patients at baseline, and
the plasma was isolated and stored at −70 °C until analysis.
Concentrations of VEGF-A, VEGF-C, soluble VEGFR-2,
vascular cell adhesion molecule 1 (VCAM-1), and E-selectin
were quantified using enzyme-linked immunosorbent assay
kits (R & D Systems, Minneapolis, MN). All assays were
performed in duplicates.
Statistical analysis
We utilized a full analysis set (FAS), defined as all patients
who met the eligibility criteria. All patients were included in
the FAS. The rate of DLT, number of patients, incidence rate
of all adverse drug reactions, PK, and efficacy were deter-
mined. Efficacy was assessed in terms of the RR, DCR, TTP,
Fig. 1 Administration schedule
of the TSU-68 plus S-1
combination. Patients received
400mg/day TSU-68 and 50, 80 or
100 mg/day S-1. The initial dose
and treatment duration for S-1
were at level 1B followed by
progression to levels 2A–2B in
case of dose-limiting toxicity
(DLT)≤2/6 or levels 1A-0A in
case of DLT≥3/6
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and OS. The median TTP and OS were assessed using the
Kaplan-Meier method, and 95 % confidence intervals (CI)
were calculated. In addition, the relationship between TTP and
endothelial cell markers at baseline was examined. TTP was
assessed at high and low levels of endothelial cell markers.
Hazard ratios (HRs) and 95%CIs were estimated by using the
Cox proportional-hazards model. Changes in biomarker con-
centrations from baseline were evaluated using the exact-




Between December 2008 and June 2010, 18 patients (6 each
at levels 1B, 2A, and 2B) were enrolled at National Cancer
Center East, National Cancer Center, and The University of
Tokyo Hospital in Japan. Baseline demographics and disease
characteristics are summarized in Table 1.
Evaluation of liver function revealed that all 18 patients
had Child-PughA cirrhosis. Of these, 7 patients (38.9%) were
at an intermediate stage and 11 (61.1 %) were at an advanced
stage according to the Barcelona-Clinic Liver Cancer staging
system [23, 24]. Seven (38.9 %) patients had previously
undergone surgeries and 15 (83.3 %) had previously received
local therapy. None of the 18 patients had ever received
sorafenib.
Dose delivery
Eighteen patients (6 each at levels 1B, 2A, and 2B) received
400 mg of TSU-68 orally per day and one of the following
doses of S-1: 80 mg/day (level 1) or 100 mg/day (level 2). For
levels 1B–2B, the median relative dose intensities of TSU-68
were 70.0 %, 76.9 %, and 87.1 %, respectively, and the
corresponding values for S-1 were 70.9 %, 75.4 %, and
87.0 %, respectively. The median duration of TSU-68 treat-
ment was 83.3 days for level 1B, 49.8 days for level 2A, and
225.8 days for level 2B; the corresponding median durations
of S-1 treatment were 67.8 days, 36.5 days, and 159.5 days,
respectively.
Safety
Two patients at level 1B exhibited DLTs. The first patient
experienced grade 3 gastrointestinal bleeding, grade 3 gastric
ulcer, grade 4 hemoglobin, grade 3 nausea, and grade 3
vomiting, while the second patient had grade 2 ascites.
At level 2A, two patients of DLTs were reported, one of
grade 3 fatigue and the other of grade 3 hand-foot skin
reaction and grade 3 rash. However, no DLTs were observed
at level 2B.
Table 2 shows the drug-related adverse reactions reported
in at least 40 % of all patients or at≥grade 3. The most
common adverse events, regardless of grade, were a decreased
hemoglobin level (83.3 %), anorexia (77.8 %), hypoalbumin-
emia (72.2 %), localized edema (66.7 %), fatigue (61.1 %),
nausea (61.1 %), a decreased platelet count (61.1 %), urine
color change (55.6 %), hyperbilirubinemia (50.0 %), exfolia-
tive rash (50.0 %), and hyperpigmentation (50.0 %). The most
common grade 3 or 4 hematological toxic effect was lympho-
penia (22.2 %), while the most common non-hematological
toxic effects were fatigue (22.2 %), anorexia (16.7 %), and an
elevated serum AST level (16.7 %).
One patient treated at level 2A died of heart failure. Three
patients at level 1B and 2A and 1 patient at level 2B were
hospitalized because of serious adverse events. Treatment was
discontinued in 3 patients because of an adverse reaction of≥
Table 1 Patient characteristics
Abbreviations: ECOG perfor-
mance status, Eastern Coopera-
tive Oncology Group perfor-
mance status
HBs Ag, hepatitis B surface anti-
gen; HCV Ab, hepati t is C
antibody
BCLC stage, Barcelona-Clinic
Liver Cancer staging system
Variable Category Level 1B Level 2A Level 2B Total
Number of patients Total 6 6 6 18
Sex Male 5 6 4 15
Female 1 0 2 3
Age (years) Median 72.5 74 65.5 71.5
Range 58-75 64-85 60-73 58-85
ECOG performance status 0 6 4 6 16
1 0 2 0 2
Viral markers HBs Ag+ 1 2 0 3
HCVAb+ 3 4 5 12
BCLC stage Intermediate 1 3 3 7
Advanced 5 3 3 11
Child-Pugh status A 6 6 6 18
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grade 3, including grade 4 pericardial effusion/grade 4 pleural
effusion, grade 3 fatigue, and grade 3 hand-foot reactions/
grade 3 rash.
PK
The PK parameters of TSU-68 after co-administration with
S-1 were the same for level 1B and 2A, as shown in Fig. 2. In
addition, these PK parameters were similar to those for TSU-
68 administered alone.
The PK parameters of S-1 components and 5-FU at level
2Awere slightly higher than the corresponding values at level
1B, as expected after the dose increase. The Cmax and AUC of
5-FU, CDHP, and Oxo were not markedly different between
day 1 and day 8, while those of FTwere higher on day 8 than
on day 1 because of accumulated exposure with repeated
administration of S-1.
Efficacy
The anti-tumor effect of TSU-68 and S-1 was evaluated in the
18 patients included in the FAS (Table 3). At level 1B, 1 of the
6 patients showed partial response (PR), corresponding to a
response rate of 16.7 %. At level 2B, 4 patients had PR,
corresponding to a response rate of 66.7 %.
The median TTP was 3.9 months at level 1B, 2.4 months at
level 2A, 8.0 months at level 2B, and 5.3 months for all
patients (Fig. 3). OS was evaluated for 18 patients in the
FAS and was 10.7 months at level 1B, 14.9 months at level
2A, 16.3 months at level 2B, and 12.8 months for all patients
(Fig. 3).
Endothelial cell markers
Biomarker analysis showed that TTP was significantly longer
in patients with low VCAM-1 levels than that in other patients
Table 2 Adverse drug reactions
according to grade (n=18) ob-
served in the study population
Results are expressed as the worst
TSU-68 or S-1-related adverse
event that occurred in at least 40%
of patients or were classified as
grade ≥3
All adverse events are document-
ed according to the National Can-
cer Institute Common
Toxicity Criteria version 3.0
Abbreviations: pts, number of pa-
tients; Gr ≥3, grade ≥3
Level 1B Level 2A Level 2B Total
pts Gr ≥3 pts Gr ≥3 pts Gr ≥3 pts Gr ≥3
Hemoglobin decrease 4 2 6 0 5 0 15 2
Anorexia 5 0 5 2 4 1 14 3
Hypoalbuminemia 4 0 4 0 5 0 13 0
Localized edema 4 0 4 0 4 0 12 0
Fatigue 4 1 3 2 4 1 11 4
Nausea 4 1 4 0 3 0 11 1
Platelet count decrease 4 0 5 1 2 0 11 1
Urine color change 4 0 3 0 3 0 10 0
Hyperbilirubinemia 2 1 4 0 3 0 9 1
Exfoliative rash 4 0 3 1 2 0 9 1
Skin hyperpigmentation 2 0 3 0 4 0 9 0
Lymphopenia 3 2 4 2 1 0 8 4
Aspartate aminotransferase level increase 4 2 1 1 3 0 8 3
Neutrophil count decrease 3 0 2 1 3 1 8 2
Hyponatremia 3 2 3 0 1 0 7 2
Vomiting 3 1 2 0 2 0 7 1
Alanine aminotransferase level increase 2 1 2 1 1 0 5 2
Hypokalemia 2 1 1 1 0 0 3 2
Hand-foot skin reaction 0 0 2 1 1 0 3 1
Pleural effusion 1 0 1 1 0 0 2 1
Gastric hemorrhage 1 1 0 0 0 0 1 1
Gastric ulcer 1 1 0 0 0 0 1 1
Liver abscess 0 0 0 0 1 1 1 1
Thrombosis 0 0 1 1 0 0 1 1
Blood glucose decrease 1 1 0 0 0 0 1 1
Myocardial ischemia 0 0 0 0 1 1 1 1
Pericardial effusion 0 0 1 1 0 0 1 1
Cardiac failure 0 0 1 1 0 0 1 1
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(hazard ratio, 0.26; 95 % CI, 0.08–0.85; p=0.018) (Table 4).
No significant difference was observed with other endothelial
cell markers examined.
Discussion
In the present study, we determined the recommended dose of
the TSU-68 plus S-1 combination in patients with advanced
HCC based on the frequency of associated DLTs. We also
investigated the safety, tolerability, PK, and efficacy of the
TSU-68 plus S-1 combination in our study population. For
combination therapy, it is important to achieve efficacy with-
out worsening of PK parameters or adverse drug reactions.
Investigation of molecular markers in TSU-68 plus S-1 com-
bination therapy merits additional research.
We determined the safety of several treatment levels by
examining the frequency of associated DLTs. Such events
were observed in 2 patients at level 1B (1 with gastrointestinal
bleeding, gastric ulcer, hemoglobin, nausea, and vomiting,
and the other 1 with ascites) and in 2 patients at level 2A (1
with fatigue and the other 1 with hand-foot skin reaction and
rash). However, at level 2B, none of the patients demonstrated
DLTs. With regard to adverse drug reactions of grade 3 or
higher severity, 17 events were noted at levels 1B and 2A and
5 events were noted at level 2B. Overall, treatment at level 2B
resulted in the least severe DLTs, less serious adverse events,
and fewer adverse reactions of grade 3 or higher severity.
When we compared the adverse drug reaction incidence in
this trial with those reported in independent trials for TSU-68
[9] and S-1 [12], in which each agent was administered alone to
patients with HCC, we found that TSU-68 plus S-1 combina-
tion therapy did not increase adverse drug reactions. Compared
to the trial in which TSU-68 was administered alone, the
incidences of anorexia, localized edema, fatigue, nausea, skin
pigmentation, hemoglobin level decrease, hypoalbuminemia,
Fig. 2 Pharmacokinetics analysis of data from 12 patients at levels 1B
and 2A. The results indicated that the areas under the curve (AUC) of
TSU-68 and 5-FU were unlikely to be affected by the combined admin-
istration of TSU-68 plus S-1. The AUC of FTappeared to decrease on the
administration of TSU-68 plus S-1 compared to that on S-1 alone.
However, other components were not affected by the administration of
TSU-68 plus S-1 in combination compared to that of S-1 alone
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thrombopenia, and hyperbilirubinemia were higher in the pres-
ent study by more than 20 %. However, compared to the trial in
which S-1 was administered alone, the incidences of localized
edema and nausea in the present study were higher by more
than 20 % while those of some other adverse drug reactions
were lower by more than 20 %. Nevertheless, there was no
difference in the adverse drug reaction rate between the TSU-68
and S-1 combination therapy and TSU-68 or S-1 administered
alone. The common adverse drug reactions of the TSU-68 plus
S-1 combination were mild in severity (grades 1–2). Our results
demonstrated that the TSU-68 plus S-1 combination was well
tolerated in patients with HCC.
We compared the PK data on TSU-68 plus S-1 combination
therapy with the PK data on S-1 or TSU-68 alone [9, 12]. Our
results suggested that TSU-68 PK parameters were unlikely to be
affected by co-administration with S-1. The Cmax and AUC of
TSU-68 on day 8were lower than those on day 1 for cytochrome
P450 1A2, as has been reported previously [9]. For S-1, exposure
to FT after repeated co-administration with TSU-68 tended to be
lower than that reported previously for S-1 administered alone
[12]. However, there were no apparent differences in the PK
parameters of 5-FU, CDHP, and Oxo between the two studies.
Our data indicated that the PK parameters of TSU-68 and S-1
were independent and hence, unaffected by combined adminis-
tration, with the exception of exposure to FT.
Next, we compared the effectiveness of TSU-68 and S-1
administered alone and in combination. TTP and OS for the 18
patients receiving TSU-68 plus S-1 combination therapy were
5.3 months and 12.8 months, and 8.0 months and
16.3 months at level 2B, respectively. On the other hand,
the progression-free survival (PFS) and OS for patients re-
ceiving S-1 alone were 3.7 months and 16.6 months, respec-
tively, and the TTP and OS for patients with TSU-68 alone
were 2.1 months and 13.1 months. Therefore, the efficacy of
the combination therapy at level 2B treatment was better
than that of either TSU-68 or S-1 treatment alone.
We also compared the efficacy of the TSU-68 plus S-1
combination administered at level 2B in this study to that of
sorafenib plus S-1 [14] and sorafenib plus Dox [15]. The PFS
was 3.9 months and 6.0 months for sorafenib plus S-1 and
sorafenib plus Dox, respectively, while the corresponding OS
was 10.4 months and 13.7 months, respectively. Therefore, the
efficacy of level 2B treatment was better than that of the other
two reported combinations.
Taken together, our results indicate that the TSU-68 plus
S-1 combination therapy is safe and efficacious; nevertheless,
further investigation of the treatment at level 2B, in particular,
is warranted.
Table 3 Efficacy results in all patients
Level 1B Level 2A Level 2B
(n=6) (n=6) (n=6)
Complete response, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Partial response, n (%) 1 (16.7) 0 (0.0) 4 (66.7)
Stable disease, n (%) 2 (33.3) 3 (50.0) 1 (16.7)
Progressive disease, n (%) 3 (50.0) 3 (50.0) 1 (16.7)
Not evaluated, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Response rate, n (%) 1 (16.7) 0 (0.0) 4 (66.7)
95 % CI (%) 0.4–64.1 0.0–45.9 22.3–95.7
Disease control rate, n (%) 3 (50.0) 3 (50.0) 5 (83.3)
95 % CI (%) 11.8–88.2 11.8–88.2 35.9–99.6
Median TTP (month) 3.9 2.4 8
95 % CI (month) 2.5–6.3 1.9– - 5.3–12.2
MST (month) 10.7 14.9 16.3
95 % CI (month) 5.7– - 11.3–20.8 11.6– -
Abbreviations: n, number; TTP, time to progression; MST, median sur-
vival time
Fig. 3 Kaplan-Meier analysis demonstrating the time to progression (a) and overall survival (b) of advanced hepatocellular carcinoma patients treated
with the TSU-68 plus S-1 combination
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Furthermore, we evaluated expression of endothelial cell
markers in patients receiving the TSU-68 plus S-1 combination
therapy. VCAM-1 is aberrantly expressed in breast cancer cells
and mediates pro-metastatic tumor-stroma interactions [25, 26].
In HCC, serumVCAM-1 level appears to reflect the severity of
the underlying chronic liver disease rather than the tumor status
[27, 28], and low preoperative serum VCAM-1 levels are
predictive of better disease-free survival after surgery [28].
Our results suggest that the VCAM-1 level may be used as a
predictive factor for TSU-68 plus S-1 combination therapy.
However, these data are preliminary and further research will
be needed to confirm the relationship between VCAM-1 and
prognosis in TSU-68 plus S-1 combination therapy.
In conclusion, our findings reveal that the TSU-68 plus S-1
recommended dose for advancedHCC is 400mg/day TSU-68
and 100 mg/day S-1 for 4 weeks followed by 2-week rest.
TSU-68 plus S-1 combination was well tolerated and had
favorable efficacy in patients with advanced HCC.
Biomarker analysis showed that VCAM-1 may be a possible
predictive marker for response. Further study is necessary to
confirm whether TSU-68 plus S-1 combination therapy is a
therapeutic option for advanced HCC and if VCAM-1 is a
possible predictive marker for response.
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PDGF-AA, platelet-derived growth factor AA
VEGF, vascular endothelial growth factor
sVEGFR-2, soluble vascular endothelial growth factor receptor 2
VEGF-C, vascular endothelial growth factor C
VEGFR-3, vascular endothelial growth factor receptor 3
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